Emerging markets often get framed as a theoretical cost play. In practice, their real value shows up somewhere else entirely: enrollment speed, data diversity, and regulatory outcomes. This article breaks down why emerging markets matter for sponsors running multi-regional clinical trials (MRCTs) — with an eye on what actually moves trial performance metrics, not just abstract advantages.
TL;DR
- Large, treatment-naive populations with high disease burden can accelerate recruitment in the right indications
- Lower site and labor costs stretch trial budgets further, supporting bigger or better-powered studies
- Genetic and environmental diversity strengthens data generalizability across global patient populations
- Skipping emerging markets risks incomplete safety data and slower access to therapies for underserved patients
- Success depends on strong local partnerships, active site oversight, and country-specific regulatory expertise
What Are Emerging Markets in Clinical Development?
Emerging markets in this context are countries with growing healthcare infrastructure and large patient pools — often classified as low- and middle-income countries (LMICs) — that are increasingly used as trial sites. Think regions across Asia, Africa, the Middle East, and Latin America. These markets typically appear in Phase II-IV multi-regional clinical trials (MRCTs), where a single protocol runs across multiple regions simultaneously. Sponsors use them to accelerate development timelines and broaden access to new therapies for populations that have historically been underrepresented in trial data.
Key Advantages of Including Emerging Markets in Clinical Trials
The advantages below tie to metrics sponsors already track: enrollment speed, cost, and data quality. None of this is abstract — it shows up on trial performance dashboards.
Faster Patient Recruitment and Enrollment
Large populations with high prevalence of target diseases, many of them treatment-naive, help sites hit enrollment targets faster. This matters because slow-recruiting sites in high-income countries are a well-known bottleneck in MRCTs.
An HHS report on clinical trial costs cites an industry account that participants in India were found in about half the time required in Western countries, while separately noting that US investigators often enroll fewer patients than investigators elsewhere.
These are directional signals, not universal guarantees. Recruitment speed still depends heavily on indication, site readiness, and competing studies in the region.
KPIs impacted:
- Enrollment rate and time-to-first-patient-in
- Overall trial duration
- Screen failure rate
When this matters most: rare disease trials, large Phase III studies, or indications where patient competition among trials is fierce.
Cost-Efficiency Without Compromising Quality
Lower operational, staffing, and site costs in many emerging markets let sponsors stretch budgets further, often enabling larger sample sizes or additional trial arms within the same spend.
The mechanism is straightforward: physician, nurse, and coordinator salaries, along with site payments, tend to run lower outside the US and Western Europe. That said, sponsors should build country-specific cost models rather than rely on blanket percentage-savings claims, since regulatory, infrastructure, and data-quality overhead can offset nominal savings.
KPIs impacted:
- Cost-per-patient and cost-per-enrolled-subject
- Overall budget utilization
When this matters most: smaller biopharma companies, or generics/hybrid product developers working with limited R&D budgets.
Genetic and Environmental Diversity Strengthening Data Quality
Emerging market populations bring genetic, dietary, and environmental variability that's often missing from homogeneous trial pools in developed markets. That variability helps identify differential drug responses across ethnic and genetic subgroups before a product reaches the broader market.
ICH E17 guidance formalizes this logic for MRCTs: sponsors should identify relevant intrinsic and extrinsic factors early, allocate sample size strategically, and evaluate whether treatment effects stay consistent across regions. ICH treats this as a scientific requirement for credible global label claims.
FDA's postmarketing guidance adds a practical warning: when a population isn't adequately represented before approval, the agency may require postmarketing studies to address differential pharmacokinetics, efficacy, or safety. Getting the diversity right upfront avoids that scramble later.
KPIs impacted:
- Data generalizability
- Adverse event detection rate
- Post-market safety signal frequency
When this matters most: chronic disease therapies, oncology, and any drug intended for global commercial launch.
What Happens When Emerging Markets Are Overlooked in Trial Design
Skipping emerging markets creates downstream problems that are harder to fix after the fact:
- Slows overall enrollment and extends trial timelines
- Produces data that underrepresents global patient diversity and leaves safety profiles incomplete
- Misses chances to study drugs against local disease burdens such as malaria, TB, or HIV
- Delays post-approval access planning for patients in excluded regions
- Raises long-term costs through smaller, less statistically powered trials
A 2025 JAMA Network Open analysis found that just under one-third of high-income-country-led cancer trials between 2014 and 2017 enrolled LMIC patients, and only 8% of phase 3 oncology trials were led by LMIC investigators. That representation gap leaves regulators and prescribers with less direct evidence on how a treatment performs across the populations who will eventually use it.
How to Get the Most Value from Emerging Market Trial Sites
Emerging market inclusion only pays off when it's backed by real infrastructure, not a checkbox on the protocol. That means strong local presence, regulatory navigation, and consistent oversight from day one.
A few things matter most:
- Partner across regions, not country-by-country. An organization with regulatory expertise across multiple emerging regions beats stitching together a different vendor for every country.
- Keep oversight active throughout the trial. On-the-ground data management, patient safety monitoring, and GxP-compliant site oversight need to run continuously, not just at study startup.
- Match local knowledge to global standards. Regional teams should understand both the local regulatory pathway and the sponsor's global compliance requirements.
DRK Research Solutions' network spans Europe, the Middle East, Asia, Africa, and the Americas, pairing local regulatory fluency with hands-on multi-regional trial experience. Sponsors can fold emerging-market sites into a global development program without giving up quality or compliance.
Conclusion
Emerging markets matter because they deliver three capabilities global clinical development programs now depend on:
- Faster enrollment in high-prevalence populations
- Lower per-patient trial costs without sacrificing quality
- Broader demographic and genetic data for stronger submissions
Those advantages compound when diverse, underserved populations are built into protocol design from the start—not added later as a budget fix.
For sponsors, emerging-market inclusion should be a standing part of global trial strategy. Plan site selection, regulatory pathways, and data standards early, and work with partners who already operate across both established and emerging regions so execution stays consistent from first patient in to database lock.
Frequently Asked Questions
Which country is best for clinical research?
There's no single "best" country. The right choice depends on disease burden, regulatory maturity, and infrastructure. India, Pakistan, and parts of Southeast Asia and Africa offer especially strong patient recruitment potential.
Why are emerging markets increasingly used in global clinical trials?
They offer faster recruitment through large, treatment-naive patient pools, lower operational costs, and population diversity that strengthens data generalizability. Together, these factors help sponsors run more efficient, better-powered trials.
What are the biggest risks of running trials in emerging markets?
Regulatory variability, infrastructure gaps, and inconsistent data quality standards top the list. Strong local oversight and country-specific due diligence are essential to managing these risks.
How do emerging market trials affect drug approval timelines?
Faster enrollment can shorten time-to-database-lock. Diverse regional data can also strengthen submission packages by showing consistent treatment effects across populations.
Do patients in emerging markets get access to approved therapies after trials?
Not always. Access planning often lags behind trial participation. Sponsors should build funded, time-bound post-trial access commitments into the protocol before enrollment begins.
What role do CROs play in emerging market clinical trials?
CROs provide local regulatory expertise, site management, and data oversight that keep trials compliant with ICH-GCP and regional requirements. That local-plus-global model is often what turns emerging-market sites into reliable sources of quality data.
